Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that it will present data on eneboparatide, the company’s investigational lead product candidate for the treatment of hypoparathyroidism, at the 39th Congress of the French Society of Endocrinology, being held October 4-7, 2023, in Marseille, France.

Complete press release Amolyt Pharma